Although the standard U-2 OS cell line was used as a pilot study to establish both localized and metastatic disease models in mice, the patient-derived tumor cell line OS9 was used to evaluate in vivo FH FOLR1-CART activity in a metastatic model. This evidence concerns the gene CARTPT and metastatic neoplasm.